Erratum: Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma(British Journal of Cancer (2015) 113 (107-118) 10.1038/bjc.2015.179);Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma

British Journal of Cancer

Volumn 113, Issue 1, 2015, Pages 107-118

  McCormick Matthews, L H ^a   Noble, F ^a,b   Tod, J ^a   Jaynes, E ^b   Harris, S ^a   Primrose, J N ^a,b   Ottensmeier, C ^a   Thomas, G J ^a,b   Underwood, T J ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Immunohistochemistry; meta analysis; molecular; oesophageal adenocarcinoma; oesophageal cancer; oesophagus; prognosis

Indexed keywords

BIOLOGICAL MARKER; CD3 ANTIGEN; CD8 ANTIGEN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LGR5 RECEPTOR; PROTEIN P53; RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; MOLECULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW; ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; METABOLISM; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84934439642     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.460     Document Type: Erratum

References (121)

1. Altman DG (2001) Systematic reviews of evaluations of prognostic variables. BMJ 323(7306): 224-228.
2. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16(4): 1340-1349.
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742): 687-697.
4. Becker L, Huang Q, Mashimo H (2010) Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. Dis Esophagus 23(2): 168-174.
5. Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, Feith M, Drecoll E, Hofler H, Langer R (2013) Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. Hum Pathol 44(5): 829-836.
6. Bellini MF, Cadamuro AC, Succi M, Proenca MA, Silva AE (2012) Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol 2012: 891961.
7. Bhandari P, Bateman AC, Mehta RL, Stacey BS, Johnson P, Cree IA, Di Nicolantonio F, Patel P (2006) Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer 6: 134.
8. Bian YS, Osterheld MC, Bosman FT, Benhattar J, Fontolliet C (2001) p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 14(5): 397-403.
9. Birner P, Jesch B, Friedrich J, Riegler M, Zacherl J, Hejna M, Wrba F, Schultheis A, Schoppmann SF (2011) Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression. Ann Surg Oncol 18(12): 3330-3337.
10. Birner P, Jesch B, Schultheis A, Schoppmann SF (2012) RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases. Clin Exp Metastasis 29(6): 551-559.
11. Bullwinkel J, Baron-Luhr B, Ludemann A, Wohlenberg C, Gerdes J, Scholzen T (2006) Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 206(3): 624-635.
12. Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus GJ, Van Lanschot JJ, Ristimaki A (2002) Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122(7): 1800-1807.
13. Casson AG, Evans SC, Gillis A, Porter GA, Veugelers P, Darnton SJ, Guernsey DL, Hainaut P (2003) Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 125(5): 1121-1131.
14. Casson AG, Kerkvliet N, O'Malley F (1995) Prognostic value of p53 protein in esophageal adenocarcinoma. J Surg Oncol 60(1): 5-11.
15. Casson AG, Tammemagi M, Eskandarian S, Redston M, McLaughlin J, Ozcelik H (1998) p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol 51(2): 71-79.
16. Cavazzola LT, Rosa AR, Schirmer CC, Gurski RR, Telles JP, Mielke F, Meurer L, Edelweiss MI, Kruel CD (2009) Immunohistochemical evaluation for P53 and VEGF (Vascular Endothelial Growth Factor) is not prognostic for long term survival in end stage esophageal adenocarcinoma. Rev Col Bras Cir 36(1): 24-34.
17. Chan DS, Twine CP, Lewis WG (2012) Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J Gastrointest Surg 16(10): 1821-1829.
18. Chandra RK, Bentz BG, Haines 3rd GK, Robinson AM, Radosevich JA (2002) Expression of glutathione s-transferase pi in benign mucosa, Barrett's metaplasia, and adenocarcinoma of the esophagus. Head Neck 24(6): 575-581.
19. Chen M, Cai E, Huang J, Yu P, Li K (2012) Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 21(7): 1126-1134.
20. Chen M, Huang J, Zhu Z, Zhang J, Li K (2013) Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer. BMC Cancer 13(1): 539.
21. Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero S, Piazza M, Blandamura S, Segalin A, Bonavina L, Peracchia A (1997) p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 79(3): 425-432.
22. Corley DA, Kerlikowske K, Verma R, Buffler P (2003) Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and metaanalysis. Gastroenterology 124(1): 47-56.
23. Courrech Staal EF, Smit VT, van Velthuysen ML, Spitzer-Naaykens JM, Wouters MW, Mesker WE, Tollenaar RA, van Sandick JW (2011) Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. Eur J Cancer 47(3): 375-382.
24. Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF (2000) Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 192(1): 14-18.
25. Dahlin AM, Henriksson ML, Van Guelpen B, Stenling R, Oberg A, Rutegard J, Palmqvist R (2011) Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 24(5): 671-682.
26. de Azambuja E, Cardoso F, de Castro Jr G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br J Cancer 96(10): 1504-1513.
27. DiMaio MA, Kwok S, Montgomery KD, Lowe AW, Pai RK (2012) Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping. Hum Pathol 43(11): 1799-1807.
28. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG (1995) The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 221(6): 677-683, discussion 683-684.
29. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A, Saksena G, Voet D, Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC, Guiducci C, Beroukhim R, Zhou Z, Lin L, Lin J, Reddy R, Chang A, Landrenau R, Pennathur A, Ogino S, Luketich JD, Golub TR, Gabriel SB, Lander ES, Beer DG, Godfrey TE, Getz G, Bass AJ (2013) Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45(5): 478-486.
30. Dutta S, Going JJ, Crumley AB, Mohammed Z, Orange C, Edwards J, Fullarton GM, Horgan PG, McMillan DC (2012) The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. Br J Cancer 106(4): 702-710.
31. Ekman S, Dreilich M, Lennartsson J, Wallner B, Brattstrom D, Sundbom M, Bergqvist M (2008) Esophageal cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther 8(9): 1433-1448.
32. Evangelou K, Kotsinas A, Mariolis-Sapsakos T, Giannopoulos A, Tsantoulis PK, Constantinides C, Troupis TG, Salmas M, Kyroudis A, Kittas C, Gorgoulis VG (2008) E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol 61(5): 601-605.
33. Falkenback D, Nilbert M, Oberg S, Johansson J (2008) Prognostic value of cell adhesion in esophageal adenocarcinomas. Dis Esophagus 21(2): 97-102.
34. Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, Madhusudan S (2009) Biomarkers of response to therapy in oesophago-gastric cancer. Gut 58(1): 127-143.
35. Flejou JF, Paraf F, Potet F, Muzeau F, Fekete F, Henin D (1994) p53 protein expression in Barrett's adenocarcinoma: a frequent event with no prognostic significance. Histopathology 24(5): 487-489.
36. France M, Drew PA, Dodd T, Watson DI (2004) Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy. Dis Esophagus 17(2): 136-140.
37. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795): 1960-1964.
38. Gowryshankar A, Nagaraja V, Eslick GD (2014) HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol 5(1): 25-35.
39. Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102(1): 37-46.
40. Grimm M, Lazariotou M, Kircher S, Stuermer L, Reiber C, Hofelmayr A, Gattenlohner S, Otto C, Germer CT, von Rahden BH (2010) MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Transl Med 8: 99.
41. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646-674.
42. Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, Rahamin J, Alderson D (1997) Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol 23(1): 30-35.
43. Heeren P, Plukker J, van Dullemen H, Nap R, Hollema H (2005) Prognostic role of cyclooxygenase-2 expression in esophageal carcinoma. Cancer Lett 225(2): 283-289.
44. Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P, Goff D, Singh R, Roa JC, Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey A, Maitra A (2010) The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 10(10): 1009-1018.
45. Heeren PA, Kloppenberg FW, Hollema H, Mulder NH, Nap RE, Plukker JT (2004) Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus. Anticancer Res 24(4): 2579-2583.
46. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5): 1011-1027.
47. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327(7414): 557-560.
48. Hong L, Han Y, Yang J, Zhang H, Jin Y, Brain L, Li M, Zhao Q (2013) Prognostic value of epidermal growth factor receptor in patients with gastric cancer: a meta-analysis. Gene 529(1): 69-72.
49. Hu Y, Bandla S, Godfrey TE, Tan D, Luketich JD, Pennathur A, Qiu X, Hicks DG, Peters JH, Zhou Z (2011) HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 24(7): 899-907.
50. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5): 341-354.
51. Jamieson NB, Carter CR, McKay CJ, Oien KA (2011) Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 17(10): 3316-3331.
52. Jiao X, Eslami A, Ioffe O, Kwong KF, Henry M, Zeng Q, Refaely Y, Burrows W, Gamliel Z, Krasna MJ (2003) Immunohistochemistry analysis of micrometastasis in pretreatment lymph nodes from patients with esophageal cancer. Ann Thorac Surg 76(4): 996-999, discussion 999-1000.
53. Kadri SR, Lao-Sirieix P, O'Donovan M, Debiram I, Das M, Blazeby JM, Emery J, Boussioutas A, Morris H, Walter FM, Pharoah P, Hardwick RH, Fitzgerald RC (2010) Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 341: c4372.
54. Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM (2004) Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg 127(6): 1579-1586.
55. Kyzas PA, Denaxa-Kyza D, Ioannidis JP (2007) Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43(17): 2559-2579.
56. Laerum OD, Ovrebo K, Skarstein A, Christensen IJ, Alpizar-Alpizar W, Helgeland L, Dano K, Nielsen BS, Illemann M (2012) Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry. Int J Cancer 131(3): 558-569.
57. Lagorce C, Paraf F, Vidaud D, Couvelard A, Wendum D, Martin A, Flejou JF (2003) Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 42(5): 457-465.
58. Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Hofler H, Sarbia M (2006) Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 59(6): 631-634.
59. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29(36): 4803-4810.
60. Liu X, Wong A, Kadri SR, Corovic A, O'Donovan M, Lao-Sirieix P, Lovat LB, Burnham RW, Fitzgerald RC (2014) Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett's esophagus. PLoS One 9(4): e94163.
61. Loos M, Langer R, Schuster T, Gertler R, Walch A, Rauser S, Friess H, Feith M (2011) Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma. Ann Thorac Surg 91(4): 1025-1031.
62. Madani K, Zhao R, Lim HJ, Casson AG (2010) Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study. Eur J Cardiothorac Surg 37(6): 1427-1432.
63. Mahipal A, Kothari N, Gupta S (2014) Epidermal growth factor receptor inhibitors: coming of age. Cancer Control 21(1): 74-79.
64. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Ollivier JM, Bonvalot S, Gignoux M (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11): 2680-2686.
65. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, Lafitte JJ, Sculier JP (2004) Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91(12): 2018-2025.
66. McDermott DF, Atkins MB (2013) PD-1 as a potential target in cancer therapy. Cancer Med 2(5): 662-673.
67. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCIEWGoCD (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4): 387-391.
68. Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, Peng H, Cui L, Li C (2014) Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer 110(6): 1595-1605.
69. Mobius C, Stein HJ, Spiess C, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert JR (2005) COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J Surg Oncol 31(7): 755-759.
70. Moher D, Liberati A, Tetzlaff J, Altman DG. Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
71. Moskaluk CA, Heitmiller R, Zahurak M, Schwab D, Sidransky D, Hamilton SR (1996) p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol 27(11): 1211-1220.
72. Mukaida H, Toi M, Hirai T, Yamashita Y, Toge T (1991) Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 68(1): 142-148.
73. Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbeck N, Becker K, Siewert JR, Harbec N (1994) Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 73(7): 1785-1794[Erratum appears in Cancer 1994;74(8):2396]. National Oesophago-Gastric Cancer audit (2013) Second Annual Report-2013.The NHS Information Centre: London.
74. Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, Bateman AR (2013) Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol 19(48): 9282-9293.
75. O'Neill JR, Stephens NA, Save V, Kamel HM, Phillips HA, Driscoll PJ, Paterson-Brown S (2013) Defining a positive circumferential resection margin in oesophageal cancer and its implications for adjuvant treatment. Br J Surg 100(8): 1055-1063.
76. Okines AF, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, Seymour M, Coxon F, Middleton GW, Smith D, Evans L, Slater S, Waters J, Ford D, Hall M, Iveson TJ, Petty RD, Plummer C, Allum WH, Blazeby JM, Griffin M, Cunningham D (2013) Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol 24(3): 702-709.
77. Ong CA, Lao-Sirieix P, Fitzgerald RC (2010) Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis. World J Gastroenterol 16(45): 5669-5681.
78. Ong CA, Shapiro J, Nason KS, Davison JM, Liu X, Ross-Innes C, O'Donovan M, Dinjens WN, Biermann K, Shannon N, Worster S, Schulz LK, Luketich JD, Wijnhoven BP, Hardwick RH, Fitzgerald RC (2013) Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. J Clin Oncol 31(12): 1576-1582.
79. Owen J, Punt J, Stranford S (2013) Kuby immunology. 7th edn. W.H. Freeman; Palgrave: NY, USA.
80. Peng J, Shao N, Peng H, Chen LQ (2013) Prognostic significance of vascular endothelial growth factor expression in esophageal carcinoma: a meta-analysis. JBUON 18(2): 398-406.
81. Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, Zhang C, Save V, O'Donovan M, Rassl D, Alderson D, Caldas C, Fitzgerald RC. Oesophageal Cancer C, Molecular Stratification Study G (2010) A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 139(6): 1995-2004.e15.
82. Phillips BE, Tubbs RR, Rice TW, Rybicki LA, Plesec T, Rodriguez CP, Videtic GM, Saxton JP, Ives DI, Adelstein DJ (2013) Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. Dis Esophagus 26(3): 299-304.
83. Polkowski W, van Sandick JW, Offerhaus GJ, ten Kate FJ, Mulder J, Obertop H, van Lanschot JJ (1999) Prognostic value of Lauren classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 6(3): 290-297.
84. Prins MJ, Verhage RJ, ten Kate FJ, van Hillegersberg R (2012) Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma. J Gastrointest Surg 16(5): 956-966.
85. Prins MJ, Verhage RJ, Ruurda JP, ten Kate FJ, van Hillegersberg R (2013) Over-expression of phosphorylated mammalian target of rapamycin is associated with poor survival in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 66(3): 224-228.
86. Rauser S, Langer R, Tschernitz S, Gais P, Jutting U, Feith M, Hofler H, Walch A (2010) High number of CD45RO\+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma. BMC Cancer 10: 608.
87. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA (2010) Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 102(1): 165-172.
88. Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G (2007) Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 20(1): 120-129.
89. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434(7035): 843-850.
90. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J (2005) Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol 6(11): 864-870.
91. Saad RS, El-Gohary Y, Memari E, Liu YL, Silverman JF (2005) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum Pathol 36 9: 955-961.
92. Sato T, Clevers H (2013) Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340(6137): 1190-1194.
93. Sauter ER, Keller SM, Erner SM (1995) p53 correlates with improved survival in patients with esophageal adenocarcinoma. J Surg Oncol 58(4): 269-273.
94. Schoppmann SF, Jesch B, Friedrich J, Jomrich G, Maroske F, Birner P (2012) Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer. Clin Exp Metastasis 29(6): 615-624.
95. Schoppmann SF, Jesch B, Riegler MF, Maroske F, Schwameis K, Jomrich G, Birner P (2013a) Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis 30(4): 441-446.
96. Schoppmann SF, Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P (2013b) Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery 153(4): 526-534.
97. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP (2011) Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 29(7): 868-874.
98. Sobin LH, Gospodarowicz MK, Wittekind C (2010) International Union against Cancer. TNM classification of malignant tumours. 7th edn. Wiley-Blackwell: Chichester, UK.
99. Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in metaanalysis. BMJ 323(7304): 101-105.
100. Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, Konstantopoulos K, Goggins MG, Van Seuningen I, Maitra A, Montgomery EA (2012) Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol 43(10): 1755-1763.
101. Thompson SK, Sullivan TR, Davies R, Ruszkiewicz AR (2011) Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 18(7): 2010-2017.
102. Tuynman JB, Buskens CJ, Kemper K, ten Kate FJ, Offerhaus GJ, Richel DJ, van Lanschot JJ (2005) Neoadjuvant selective COX-2 inhibition downregulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg 242(6): 840-849, discussion 849-50.
103. Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ (2008) Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 98(6): 1102-1108.
104. Vallbohmer D, Lenz HJ (2006) Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 19(6): 425-432.
105. von Rahden BH, Kircher S, Lazariotou M, Reiber C, Stuermer L, Otto C, Germer CT, Grimm M (2011) LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus? J Exp Clin Cancer Res 30: 23.
106. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT (2007) Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109(4): 658-667.
107. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT (2006) Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res 12(15): 4598-4604.
108. Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, Webb A, Hampton C, Patel NN, Randall CJ, Cox HJ, Jogai S, Primrose J, Piper K, Ottensmeier CH, King EV, Thomas GJ (2014) Tumourinfiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer 110(2): 489-500.
109. Ward S, Scope A, Rafia R, Pandor A, Harnan S, Evans P, Wyld L (2013) Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Health Technol Assess 17(44): 1-302.
110. Waterman TA, Hagen JA, Peters JH, DeMeester SR, Taylor CR, Demeester TR (2004) The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann Thorac Surg 78(4): 1161-1169.
111. Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong CA, Lao-Sirieix P, Dunning MJ, Smith L, Smith ML, Anderson CL, Carvalho B, O'Donovan M, Underwood TJ, May AP, Grehan N, Hardwick R, Davies J, Oloumi A, Aparicio S, Caldas C, Eldridge MD, Edwards PA, Rosenfeld N, Tavare S, Fitzgerald RC. OCCAMMS Consortium (2014) Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 46(8): 837-843.
112. Wijnhoven BP, Pignatelli M, Dinjens WN, Tilanus HW (2005) Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction. J Surg Oncol 92(2): 116-123.
113. Wolf-Yadlin A, Kumar N, Zhang Y, Hautaniemi S, Zaman M, Kim HD, Grantcharova V, Lauffenburger DA, White FM (2006) Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Sys Biol 2: 54.
114. Xie LX, Zhai TT, Yang LP, Yang E, Zhang XH, Chen JY, Zhang H (2013) Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma. Int J Exp Pathol 94(1): 39-46.
115. Yacoub L, Goldman H, Odze RD (1997) Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett'sassociated neoplasia: correlation with prognosis. Mod Pathol 10(2): 105-112.
116. Yendamuri S, Huang M, Malhotra U, Warren GW, Bogner PN, Nwogu CE, Groman A, Demmy TL (2013) Prognostic implications of signet ring cell histology in esophageal adenocarcinoma. Cancer 119(17): 3156-3161.
117. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2): 174-183.
118. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA (2012) Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 18(2): 546-554.
119. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3): 203-213.
120. Zhu CQ, Shih W, Ling CH, Tsao MS (2006) Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59(8): 790-800.
121. Zingg U, Montani M, Frey DM, Dirnhofer S, Esterman AJ, Went P, Oertli D (2010) Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol 36(7): 670-677.